Literature DB >> 17699748

Targeting oncogenic Ras.

Ernesto Diaz-Flores1, Kevin Shannon.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17699748     DOI： 10.1101/gad.1587907

Source DB:  PubMed          Journal:  Genes Dev        ISSN： 0890-9369            Impact factor:   11.361


× No keyword cloud information.
  19 in total

1.  DNA methylation regulates cocaine-induced behavioral sensitization in mice.

Authors:  Kaili Anier; Kristina Malinovskaja; Anu Aonurm-Helm; Alexander Zharkovsky; Anti Kalda
Journal:  Neuropsychopharmacology       Date:  2010-08-18       Impact factor: 7.853

2.  Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

Authors:  Christian Posch; Homayoun Moslehi; Luzviminda Feeney; Gary A Green; Anoosheh Ebaee; Valentin Feichtenschlager; Kim Chong; Lily Peng; Michelle T Dimon; Thomas Phillips; Adil I Daud; Timothy H McCalmont; Philip E LeBoit; Susana Ortiz-Urda
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

Authors:  Atsushi Nonami; Martin Sattler; Ellen Weisberg; Qingsong Liu; Jianming Zhang; Matthew P Patricelli; Amanda L Christie; Amy M Saur; Nancy E Kohl; Andrew L Kung; Hojong Yoon; Taebo Sim; Nathanael S Gray; James D Griffin
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 4.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

5.  RAS status in Korean patients with stage III and IV colorectal cancer.

Authors:  W-S Lee; J N Lee; J-H Baek; Y H Park
Journal:  Clin Transl Oncol       Date:  2015-05-22       Impact factor: 3.405

6.  MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.

Authors:  Zhumei Shi; Qiudan Chen; Chongyong Li; Lin Wang; Xu Qian; Chengfei Jiang; Xue Liu; Xiefeng Wang; Hai Li; Chunsheng Kang; Tao Jiang; Ling-Zhi Liu; Yongping You; Ning Liu; Bing-Hua Jiang
Journal:  Neuro Oncol       Date:  2014-05-25       Impact factor: 12.300

7.  Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.

Authors:  Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

8.  The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.

Authors:  Irem Dogan Turacli; Ayla Cihan Ozkan; Abdullah Ekmekci
Journal:  Tumour Biol       Date:  2015-06-25

9.  NRAS mutations are rare in colorectal cancer.

Authors:  Natsumi Irahara; Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Liying Yan; Dora Dias-Santagata; Anthony John Iafrate; Charles S Fuchs; Kevin M Haigis; Shuji Ogino
Journal:  Diagn Mol Pathol       Date:  2010-09

10.  Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Jeffrey Eastham-Anderson; James E Cupp; Yuxin Liang; David P Davis; Klaus P Hoeflich; Somasekar Seshagiri
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.